Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
A massive document release related to Jeffrey Epstein has sparked outrage after failing to protect dozens of victims, publishing names and nude photos despite court-ordered redactions. The disclosure raises serious questions about procedural failures and victim protection.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
A second woman has come forward alleging the late financier Jeffrey Epstein arranged for her to have a sexual encounter with Prince Andrew in 2010, according to a BBC report. The claim surfaces amid renewed scrutiny following a major document release by U.S. authorities.
